Heska (NASDAQ:HSKA) Upgraded by ValuEngine to “Strong-Buy”

ValuEngine upgraded shares of Heska (NASDAQ:HSKA) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday morning, ValuEngine reports.

A number of other brokerages have also issued reports on HSKA. Guggenheim started coverage on Heska in a research report on Thursday, May 23rd. They set a neutral rating on the stock. BidaskClub lowered Heska from a hold rating to a sell rating in a research report on Tuesday. Finally, Canaccord Genuity reissued a buy rating and issued a $95.00 price objective on shares of Heska in a report on Monday, July 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $97.67.

Shares of NASDAQ HSKA traded down $2.45 during midday trading on Thursday, reaching $79.25. 74,424 shares of the company’s stock were exchanged, compared to its average volume of 61,816. Heska has a 52-week low of $68.74 and a 52-week high of $114.50. The company has a market capitalization of $621.14 million, a PE ratio of 55.81 and a beta of 1.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.66 and a quick ratio of 1.45. The stock’s fifty day moving average price is $81.51.

Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, May 7th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.19. Heska had a return on equity of 8.36% and a net margin of 3.63%. The business had revenue of $29.51 million for the quarter, compared to analyst estimates of $35.21 million. As a group, analysts expect that Heska will post 0.03 EPS for the current year.

In other news, Director Scott Humphrey acquired 1,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average cost of $73.79 per share, with a total value of $73,790.00. Following the completion of the acquisition, the director now directly owns 3,062 shares in the company, valued at $225,944.98. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.00% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in HSKA. Granite Investment Partners LLC bought a new stake in Heska in the first quarter valued at about $13,897,000. Redmile Group LLC boosted its stake in Heska by 14.3% in the first quarter. Redmile Group LLC now owns 226,013 shares of the medical research company’s stock valued at $19,238,000 after acquiring an additional 28,300 shares during the period. Geode Capital Management LLC boosted its stake in Heska by 31.8% in the fourth quarter. Geode Capital Management LLC now owns 92,734 shares of the medical research company’s stock valued at $7,984,000 after acquiring an additional 22,378 shares during the period. Martingale Asset Management L P boosted its stake in Heska by 120.9% in the first quarter. Martingale Asset Management L P now owns 29,602 shares of the medical research company’s stock valued at $2,521,000 after acquiring an additional 16,200 shares during the period. Finally, Millennium Management LLC boosted its stake in Heska by 330.6% in the fourth quarter. Millennium Management LLC now owns 18,659 shares of the medical research company’s stock valued at $1,607,000 after acquiring an additional 14,326 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

See Also: Market Capitalization in the Stock Market

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.